CNS Stimulants and Cognition Enhancers

Classification

Amphetamines: amphetamine, dextroamphetamine, methylphenidate, atomoxetine(non-stimulant, distinct mechanism). Xanthines: caffeine, theophylline(full detail: Respiratory System). Cognition enhancers: cholinesterase inhibitors(donepezil, rivastigmine, galantamine), memantine(NMDA antagonist). Analeptics(historical): doxapram.

Mechanism

Amphetamine: INDIRECT sympathomimetic — enters terminals via NA/DA transporters, displaces stored catecholamines→cytoplasm, releases via EXCHANGE DIFFUSION(reverse transport), NOT Ca2+-dependent exocytosis. IDENTICAL mechanism to TYRAMINE(Adrenergic System). Depends on intact stores → tachyphylaxis/tolerance as stores deplete with repeated dosing.

Methylphenidate: blocks DA+NA REUPTAKE(conventional inhibitor, vs amphetamine’s release-promoting mechanism) — similar net effect. Both = 1st-line ADHD. Paradox explained: prefrontal cortex needs OPTIMAL not maximal catecholamine tone for executive function; ADHD = relative prefrontal catecholamine UNDERACTIVITY → these drugs NORMALIZE(not just boost) this specific circuit — different logic from euphoriant effect at high/recreational doses or in non-ADHD individuals.

Atomoxetine: SELECTIVE NA reuptake inhibitor, distinct from amphetamine/methylphenidate(no dopaminergic/vesicular-release action). NOT controlled/scheduled(low abuse potential) → alternative for ADHD where misuse/diversion is concern, or stimulant CV/growth effects undesirable. SLOWER onset(weeks, like antidepressant) vs immediate stimulant effect.

Caffeine: non-selective ADENOSINE receptor antagonist(A1+A2A) — adenosine=inhibitory neuromodulator accumulating during wakefulness→sleepiness; blocking removes inhibitory tone→wakefulness/alertness. SAME mechanism(different receptor subtype/tissue) as theophylline’s bronchodilation(Respiratory System) — one receptor mechanism, different tissue, different therapeutic effect.

Cholinesterase inhibitors: ↓AChE→↑synaptic ACh at CENTRAL cholinergic synapses. Alzheimer’s disease(cortical/hippocampal cholinergic neuron loss, esp nucleus basalis of Meynert) → modest SYMPTOMATIC benefit only, does NOT alter underlying neurodegeneration — SYMPTOMATIC vs DISEASE-MODIFYING distinction, high-yield.

Memantine: NMDA antagonist, unrelated to cholinesterase inhibitors. Moderate-affinity, ACTIVITY-DEPENDENT blockade — preferentially blocks PATHOLOGICAL sustained low-level NMDA activation(excitotoxic neurodegeneration) while SPARING normal phasic NMDA activity(physiological synaptic transmission/memory). This selectivity = why memantine lacks ketamine’s psychotomimetic/dissociative effects at therapeutic dose. Moderate-severe Alzheimer’s, often + cholinesterase inhibitor(complementary, non-overlapping mechanisms).

Adverse Effects

Amphetamine/methylphenidate: insomnia · appetite/growth suppression in children(monitor growth long-term) · CV stimulation(tachycardia, HTN — caution underlying cardiac disease) · genuine abuse/dependence potential(dopaminergic/euphoriant at high dose) → CONTROLLED substances, careful prescribing/diversion monitoring. Distinct from atomoxetine.

Caffeine: tolerance + mild-moderate withdrawal(headache, fatigue, irritability) on abrupt cessation — adenosine-receptor MIRROR-IMAGE of chronic benzo/alcohol withdrawal logic(receptor upregulation compensating, unmasked on stopping), far LESS dangerous though. High dose: anxiety, tremor, tachyarrhythmia; severe OD: seizures.

Cholinesterase inhibitors: predictable cholinergic excess — GI upset(nausea, diarrhoea — most common, dose-limiting) · bradycardia(vagal, caution conduction disease) · ↑GI acid secretion(caution +NSAIDs, additive ulcer risk). SAME class of SE as Cholinergic System’s cholinesterase inhibitors, just at lower cognitive-enhancement doses vs myasthenia/NMB-reversal doses.

Memantine: generally well tolerated — dizziness, confusion, headache. MILDER than cholinesterase inhibitors(consistent with selective, activity-dependent mechanism).

Clinical Relevance

Connects to 2 mechanisms ALREADY established elsewhere, not new pharmacology: amphetamine = IDENTICAL mechanism to tyramine(indirect, transporter/vesicle-dependent catecholamine release); caffeine = IDENTICAL mechanism to theophylline(adenosine receptor antagonism). Recognizing SAME underlying mechanism in different clinical context (not unrelated new facts) = efficient way to hold this topic alongside Adrenergic System + Respiratory System rather than as isolated list.

Classification

Amphetamines and amphetamine-like agents: amphetamine, dextroamphetamine, methylphenidate, atomoxetine (a non-stimulant, mechanistically distinct — see below)
Xanthines: caffeine, theophylline (covered fully under Respiratory System)
Cognition enhancers/anti-dementia drugs: cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine (NMDA antagonist)
Analeptics (largely historical/limited current use): doxapram

Mechanism of Action

Amphetamine: an indirectly-acting sympathomimetic — enters presynaptic noradrenergic/dopaminergic terminals via the noradrenaline/dopamine transporters, displaces stored catecholamines from vesicles into the cytoplasm, and promotes their release by exchange diffusion (reverse transport) rather than the normal calcium-dependent exocytosis — the identical fundamental mechanism already described for tyramine under Adrenergic System, applied here to a therapeutically-used stimulant rather than an incidental dietary amine. This indirect, transporter-dependent mechanism is why amphetamine’s effect depends on intact catecholamine stores (tachyphylaxis/tolerance develops as stores deplete with repeated dosing) and why it shares the same class of drug interaction logic as other indirect sympathomimetics.

Methylphenidate: primarily blocks dopamine and noradrenaline reuptake (a more conventional reuptake-inhibitor mechanism than amphetamine’s release-promoting one, though the net effect — increased synaptic catecholamine availability — is similar) — both amphetamine and methylphenidate are first-line for attention-deficit/hyperactivity disorder (ADHD), where the therapeutic paradox (a stimulant improving attention and reducing hyperactivity, apparently opposite to its name) is explained by the prefrontal cortex’s dependence on optimal, not maximal, catecholamine (particularly dopamine and noradrenaline) tone for executive function — ADHD is associated with relative prefrontal catecholamine underactivity, and these drugs are understood to normalize rather than simply boost signalling in this specific circuit, a genuinely different pharmacological logic from their euphoriant/stimulant effect at higher recreational doses or in individuals without ADHD.

Atomoxetine: a selective noradrenaline reuptake inhibitor, mechanistically distinct from amphetamine/methylphenidate (no direct dopaminergic or vesicular-release action) and, critically, not a controlled/scheduled stimulant given its low abuse potential — a genuinely useful alternative for ADHD in patients where stimulant misuse/diversion is a specific concern, or where stimulant-associated cardiovascular/growth effects are less desirable, at the cost of a slower onset of clinical benefit (weeks, similar to an antidepressant) compared with the immediate effect of amphetamine/methylphenidate.

Caffeine: a non-selective adenosine receptor antagonist — adenosine is an inhibitory neuromodulator that accumulates during wakefulness and promotes sleepiness; blocking its receptors (A1 and A2A) removes this inhibitory tone, producing wakefulness/alertness — genuinely distinct from the catecholamine-based mechanisms above, and the same adenosine-antagonist mechanism (though at a different receptor subtype/tissue) already discussed for theophylline’s bronchodilator action under Respiratory System, illustrating how one core receptor mechanism produces different therapeutic effects depending on which tissue’s adenosine tone is being removed.

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): inhibit acetylcholinesterase, increasing synaptic acetylcholine availability at central cholinergic synapses — used in Alzheimer’s disease, where cortical/hippocampal cholinergic neuron loss (particularly from the nucleus basalis of Meynert) is a well-established, though not sole, contributor to the cognitive deficit; increasing residual cholinergic transmission provides modest symptomatic benefit (improved cognition/function for a period) without altering the underlying neurodegenerative disease course — a genuinely important distinction (symptomatic versus disease-modifying) frequently tested, since these drugs do not stop or reverse the underlying pathology.

Memantine: an NMDA receptor antagonist, mechanistically unrelated to the cholinesterase inhibitors — moderate-affinity, uses activity-dependent blockade (preferentially blocks pathologically sustained, low-level NMDA receptor activation associated with excitotoxic neurodegeneration in Alzheimer’s disease, while relatively sparing the normal, phasic NMDA activity needed for physiological synaptic transmission and memory formation) — this selectivity for pathological over physiological NMDA signalling is the specific reason memantine doesn’t produce the same psychotomimetic/dissociative effects as a non-selective NMDA antagonist like ketamine at therapeutic doses. Used in moderate-to-severe Alzheimer’s disease, often combined with a cholinesterase inhibitor (complementary, non-overlapping mechanisms).

Adverse Effects

Amphetamine/methylphenidate: insomnia, appetite suppression/growth suppression in children (a specific, monitored concern with long-term paediatric ADHD treatment, requiring periodic growth tracking), cardiovascular stimulation (tachycardia, hypertension — a specific caution in patients with underlying cardiac disease), and genuine abuse/dependence potential given the dopaminergic/euphoriant mechanism at higher doses — the reason these are controlled substances requiring careful prescribing and monitoring for diversion/misuse, distinct from atomoxetine.

Caffeine: tolerance and a genuine, generally mild-to-moderate withdrawal syndrome (headache, fatigue, irritability) on abrupt cessation after regular use — mechanistically the adenosine-receptor mirror-image of chronic benzodiazepine/alcohol withdrawal logic (receptor upregulation compensating for chronic antagonism, unmasked on stopping), though far less dangerous than those withdrawal syndromes. At high doses: anxiety, tremor, tachyarrhythmia, and, in significant overdose, seizures.

Cholinesterase inhibitors: predictable cholinergic excess — GI upset (nausea, diarrhoea — the most common, often dose-limiting adverse effects), bradycardia (vagal cholinergic effect on the heart, a specific caution in patients with conduction disease), and increased GI acid secretion (caution with concurrent NSAID use, given additive ulcer risk) — essentially the same class of adverse effect already described for cholinesterase inhibitors under the Cholinergic System, applied here at the (lower) doses used for cognitive enhancement rather than for myasthenia gravis or reversal of neuromuscular blockade.

Memantine: generally well tolerated; dizziness, confusion, headache — a comparatively mild adverse-effect profile relative to the cholinesterase inhibitors, consistent with its more selective, activity-dependent mechanism.

Clinical Relevance

This topic connects back to two mechanisms already established elsewhere in the subject rather than introducing entirely new pharmacology: amphetamine’s mechanism is identical in principle to tyramine’s (indirect, transporter/vesicle-dependent catecholamine release), and caffeine’s mechanism is identical in principle to theophylline’s (adenosine receptor antagonism) — recognizing these as the same underlying mechanism applied in a different clinical context, rather than as unrelated new facts to memorize, is the efficient way to hold this topic alongside Adrenergic System and Respiratory System rather than as an isolated list.

Amphetamine’s indirect vesicular-release mechanism, side-by-side with tyramine’s identical mechanism under Adrenergic System.
Memantine’s activity-dependent NMDA blockade distinguishing pathological sustained activation from normal phasic signalling.